Afam A. Okoye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Afam A. Okoye has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
Benjamin Varco-Merth
Vaccine and Gene Therapy Institute, Oregon Health and Science University , Beaverton, OR
7 shared publications- Louis J. Picker
Vaccine and Gene Therapy Institute, Oregon Health and Science University , Beaverton, OR
7 shared publications - Brandon F. Keele
AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research
6 shared publications Louis J. Picker
Affiliations Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America
5 shared publications- Michael K. Axthelm
Vaccine and Gene Therapy Institute and
5 shared publications Michael Nekorchuk
Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA
5 shared publications
Latest Publications
- 7 October 2026
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 42 (12) , 369-378
Safety of Autologous Infusion of CER T Cells in Nonhuman Primates
Cellular immunotherapies have shown great promise in the treatment of various diseases. Chimeric engulfment receptor (CER)-engineered T cells were developed to utilize the extracellular T-cell immunoglobulin and mucin domain-containing 4 (TIM-4) domain and intracellular engulfment signaling domains to target and enhance phagocytosis and T-cell cytotoxic function. These processes are activated through TIM-4 binding with phosphatidylserine (PS), a pro-phagocytic “eat me” signal. HIV infection has been shown to induce extracellular PS exposure shortly after infection, and engineered CER T cells have been shown to kill CD4 + T cells infected with simian immunodeficiency virus (SIV) in vitro . In this study, we infused two rhesus macaques (RMs) with CER-1236 T cells (the iteration of CER T cells currently moving forward in human clinical trials for cancer) and evaluated safety, the tissue distribution of the CER-1236 T cells, and antiviral activity against SIV (SIVmac239). Prior to infusions, RMs underwent SIV infection, antiretroviral therapy (ART), and ART cessation. The infusions were well tolerated. Neither of the macaques exhibited clinical evidence of illness nor changes in vital signs, serum chemistry, hematology, or other evaluated physiological parameters beyond what is typically observed with SIV infection. Post-infusion proliferation of CER T cells in PBMC was limited and seen with cells manufactured by the Prodigy system. Histologic and flow cytometry evaluation from post-infusion tissue biopsies and necropsy revealed tissue detection of CER T cells in bronchoalveolar lavage fluid with intermittent detection of infused cells in lymphoid tissue in concert with the limited expansion of T cells in PBMC. No laboratory or clinical evidence of hepatic, splenic, bone marrow, or CNS alterations was noted, and no evidence of in vivo suppression of SIVmac239 was observed as a result of the infusions. The CER-1236 T cell infusions were not associated with any discernable histopathological toxicity. This safety profile of CER-1236 T cells in nonhuman primates portends well for its potential for clinical development, especially for tumors with high expression of the tissue damage receptor PS. Optimization of in vivo functionality will be required for CER T cells to be effective against HIV infection.
- 7 October 2026
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 42 (12) , 369-378
Safety of Autologous Infusion of CER T Cells in Nonhuman Primates
Cellular immunotherapies have shown great promise in the treatment of various diseases. Chimeric engulfment receptor (CER)-engineered T cells were developed to utilize the extracellular T-cell immunoglobulin and mucin domain-containing 4 (TIM-4) domain and intracellular engulfment signaling domains to target and enhance phagocytosis and T-cell cytotoxic function. These processes are activated through TIM-4 binding with phosphatidylserine (PS), a pro-phagocytic “eat me” signal. HIV infection has been shown to induce extracellular PS exposure shortly after infection, and engineered CER T cells have been shown to kill CD4 + T cells infected with simian immunodeficiency virus (SIV) in vitro . In this study, we infused two rhesus macaques (RMs) with CER-1236 T cells (the iteration of CER T cells currently moving forward in human clinical trials for cancer) and evaluated safety, the tissue distribution of the CER-1236 T cells, and antiviral activity against SIV (SIVmac239). Prior to infusions, RMs underwent SIV infection, antiretroviral therapy (ART), and ART cessation. The infusions were well tolerated. Neither of the macaques exhibited clinical evidence of illness nor changes in vital signs, serum chemistry, hematology, or other evaluated physiological parameters beyond what is typically observed with SIV infection. Post-infusion proliferation of CER T cells in PBMC was limited and seen with cells manufactured by the Prodigy system. Histologic and flow cytometry evaluation from post-infusion tissue biopsies and necropsy revealed tissue detection of CER T cells in bronchoalveolar lavage fluid with intermittent detection of infused cells in lymphoid tissue in concert with the limited expansion of T cells in PBMC. No laboratory or clinical evidence of hepatic, splenic, bone marrow, or CNS alterations was noted, and no evidence of in vivo suppression of SIVmac239 was observed as a result of the infusions. The CER-1236 T cell infusions were not associated with any discernable histopathological toxicity. This safety profile of CER-1236 T cells in nonhuman primates portends well for its potential for clinical development, especially for tumors with high expression of the tissue damage receptor PS. Optimization of in vivo functionality will be required for CER T cells to be effective against HIV infection.
- Open Access
- 1 October 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (10)
Preservation of MHC-Ia protective allele suppression of SIVmac239 in aged rhesus macaques
Major histocompatibility complex class Ia (MHC-Ia)–restricted CD8⁺ T cell responses play a central role in the host defense against HIV-1, with certain MHC-Ia alleles known to be associated with cytotoxic T lymphocyte responses having an increased potential for viral control. However, the impact of immune aging on the effectiveness of such protective alleles remains unclear. In this study, we assessed SIVmac239 replication in aged (17–23 yr old) rhesus macaques (RMs) exhibiting low frequencies of naïve T cells and expanded effector memory T cells, that were further stratified by the presence (MHC⁺) or absence (MHC−) of 3 known “protective MHC-Ia alleles” (Mamu-A*01, Mamu-B*08, or Mamu-B*17). All RMs were infected with SIVmac239 and viral dynamics monitored longitudinally. MHC⁺ RMs demonstrated significantly lower plasma viral loads (PVLs) through 70 d postinfection compared with MHC− RMs. At 70 d postinfection, half of the RMs from each group initiated suppressive triple antiretroviral therapy comprising dolutegravir, emtricitabine, and tenofovir disoproxil fumarate (TDF) for 15 wk, followed by suboptimal TDF monotherapy for an additional 21 wk. While antiretroviral therapy substantially reduced PVL in both groups, viral decline was accelerated in MHC⁺ RMs relative to MHC− RMs. Moreover, upon switching to TDF monotherapy, PVL rebounded by almost 3 logs in MHC− RMs, while MHC⁺ RMs maintained viral suppression. Collectively, these findings indicate that protective MHC-Ia alleles can mediate viral control in aged hosts, even under suboptimal treatment conditions, and highlight the potential role of optimized CD8+ T cell responses in strategies targeting viral persistence in aging populations.
- 1 October 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (10)
Open AccessPreservation of MHC-Ia protective allele suppression of SIVmac239 in aged rhesus macaques
Major histocompatibility complex class Ia (MHC-Ia)–restricted CD8⁺ T cell responses play a central role in the host defense against HIV-1, with certain MHC-Ia alleles known to be associated with cytotoxic T lymphocyte responses having an increased potential for viral control. However, the impact of immune aging on the effectiveness of such protective alleles remains unclear. In this study, we assessed SIVmac239 replication in aged (17–23 yr old) rhesus macaques (RMs) exhibiting low frequencies of naïve T cells and expanded effector memory T cells, that were further stratified by the presence (MHC⁺) or absence (MHC−) of 3 known “protective MHC-Ia alleles” (Mamu-A*01, Mamu-B*08, or Mamu-B*17). All RMs were infected with SIVmac239 and viral dynamics monitored longitudinally. MHC⁺ RMs demonstrated significantly lower plasma viral loads (PVLs) through 70 d postinfection compared with MHC− RMs. At 70 d postinfection, half of the RMs from each group initiated suppressive triple antiretroviral therapy comprising dolutegravir, emtricitabine, and tenofovir disoproxil fumarate (TDF) for 15 wk, followed by suboptimal TDF monotherapy for an additional 21 wk. While antiretroviral therapy substantially reduced PVL in both groups, viral decline was accelerated in MHC⁺ RMs relative to MHC− RMs. Moreover, upon switching to TDF monotherapy, PVL rebounded by almost 3 logs in MHC− RMs, while MHC⁺ RMs maintained viral suppression. Collectively, these findings indicate that protective MHC-Ia alleles can mediate viral control in aged hosts, even under suboptimal treatment conditions, and highlight the potential role of optimized CD8+ T cell responses in strategies targeting viral persistence in aging populations.
- 11 September 2026
- Published by SAGE Publications in Human Gene Therapy
Chimeric Antigen Receptor T Cell Targeting of Natural Killer Cells in Peripheral Blood and Tissues of Rhesus Macaques
Natural killer (NK) cells lead a rapid and potent innate immune response following exposure to infectious agents, but their activity may also contribute to chronic inflammation and augmented disease pathogenesis. Previous reports have shown that Janus kinase 3 inhibitors or anti-IL-15 monoclonal antibodies potently deplete NK cells in nonhuman primates (NHPs). However, they also disrupt T cell homeostasis, making it difficult to use these reagents to delineate the nonredundant role of NK cells in NHPs. To induce the specific depletion of NK cells in vivo , we designed chimeric antigen receptor (CAR) T cells targeting either a broad (CD16 + ) or narrow (NKG2A/C + ) proportion of NK-inclusive innate immune subsets in rhesus macaques (RM). Ex vivo screening assays identified anti-CD16 and anti-NKG2A/C CAR constructs that potently and specifically depleted CD16 + and NKG2A/C + cells, respectively, in the presence of autologous peripheral blood mononuclear cells (PBMCs). Adoptive transfer of autologous anti-NKG2A/C CARs was associated with a profound depletion of NK cells in blood and tissues of RM. NK cell depletion occurred despite modest anti-NKG2A/C CAR T cell expansion and persistence. No target cell depletion was observed following anti-CD16 CAR T-cell infusion, potentially due to the CAR T-cell dose and/or infusion frequency, animal-specific factors, or limitations of the CAR construct. Collectively, our pioneering study expands the application of CAR T cells as a basic science tool and further advances the NHP model for studying NK cell activity in disease contexts, such as infectious diseases and allotransplantation.
- 11 September 2026
- Published by SAGE Publications in Human Gene Therapy
Chimeric Antigen Receptor T Cell Targeting of Natural Killer Cells in Peripheral Blood and Tissues of Rhesus Macaques
Natural killer (NK) cells lead a rapid and potent innate immune response following exposure to infectious agents, but their activity may also contribute to chronic inflammation and augmented disease pathogenesis. Previous reports have shown that Janus kinase 3 inhibitors or anti-IL-15 monoclonal antibodies potently deplete NK cells in nonhuman primates (NHPs). However, they also disrupt T cell homeostasis, making it difficult to use these reagents to delineate the nonredundant role of NK cells in NHPs. To induce the specific depletion of NK cells in vivo , we designed chimeric antigen receptor (CAR) T cells targeting either a broad (CD16 + ) or narrow (NKG2A/C + ) proportion of NK-inclusive innate immune subsets in rhesus macaques (RM). Ex vivo screening assays identified anti-CD16 and anti-NKG2A/C CAR constructs that potently and specifically depleted CD16 + and NKG2A/C + cells, respectively, in the presence of autologous peripheral blood mononuclear cells (PBMCs). Adoptive transfer of autologous anti-NKG2A/C CARs was associated with a profound depletion of NK cells in blood and tissues of RM. NK cell depletion occurred despite modest anti-NKG2A/C CAR T cell expansion and persistence. No target cell depletion was observed following anti-CD16 CAR T-cell infusion, potentially due to the CAR T-cell dose and/or infusion frequency, animal-specific factors, or limitations of the CAR construct. Collectively, our pioneering study expands the application of CAR T cells as a basic science tool and further advances the NHP model for studying NK cell activity in disease contexts, such as infectious diseases and allotransplantation.
- Open Access
Distinct phases of immune system programming during ART-suppressed immunodeficiency virus infection
People living with HIV (PLWH) on suppressive antiretroviral therapy (ART) can face non-AIDS complications, partially driven by chronic immune activation. To define immune perturbations during ART-suppressed viral infection, we performed longitudinal single-cell transcriptomic and plasma proteomic analysis of rhesus macaques infected with SIVmac239M and ART-treated for 70 weeks. We identified broad, bi-phasic immune changes. Acute infection involves an interferon-driven signature, correlated with viral replication, that largely resolves with viral control. Cell-associated virus correlated with interferon-stimulated genes in most tissues; however, this was blunted in gut-associated lymph nodes, a feature that may contribute to reservoir persistence. Separate alterations manifest 54-66 weeks-post-infection, after 40 weeks of viral suppression, including broad TGF-β and NF-kB signaling and discrete bursts of inflammatory monocytes, largely restricted to bone marrow. These data highlight the biphasic remodeling of long-term ART-suppressed HIV, identifying specific tissues and cell populations with dysregulation, with implications for the treatment of PLWH.
Open AccessDistinct phases of immune system programming during ART-suppressed immunodeficiency virus infection
People living with HIV (PLWH) on suppressive antiretroviral therapy (ART) can face non-AIDS complications, partially driven by chronic immune activation. To define immune perturbations during ART-suppressed viral infection, we performed longitudinal single-cell transcriptomic and plasma proteomic analysis of rhesus macaques infected with SIVmac239M and ART-treated for 70 weeks. We identified broad, bi-phasic immune changes. Acute infection involves an interferon-driven signature, correlated with viral replication, that largely resolves with viral control. Cell-associated virus correlated with interferon-stimulated genes in most tissues; however, this was blunted in gut-associated lymph nodes, a feature that may contribute to reservoir persistence. Separate alterations manifest 54-66 weeks-post-infection, after 40 weeks of viral suppression, including broad TGF-β and NF-kB signaling and discrete bursts of inflammatory monocytes, largely restricted to bone marrow. These data highlight the biphasic remodeling of long-term ART-suppressed HIV, identifying specific tissues and cell populations with dysregulation, with implications for the treatment of PLWH.
- Open Access
- 24 March 2026
- Published by American Society for Microbiology in Journal of Virology
- Vol. 100 (3) , e0148525
Dissecting the steps in early simian immunodeficiency virus dissemination following mucosal and intravenous infection of rhesus macaques
Early HIV infection involves the transmission of a small number of virions and the subsequent expansion and spread of the virus. The early phases of infection represent an important opportunity for viral control, although relatively little is understood about the determinants of the rate of spread or the “bottlenecks” the virus must negotiate during this time. Here, we use the barcoded simian immunodeficiency virus (SIV) infection model to analyze the kinetics of early SIV infection in vitro and in vivo . We analyze the trajectories of multiple individual barcode lineages across in vitro infection of cell lines and primary cells and after mucosal and intravenous infection of macaques. We observe a large distribution in lineage sizes when an infection is founded by multiple different viral lineages, which we presume results from bottleneck-induced variability in early growth between lineages. Surprisingly, we find that lineage heterogeneity is similar after mucosal and intravenous infection, indicating that dissemination bottlenecks present in the genital tract are not grossly different from those encountered during seeding of systemic tissues. Comparing in vitro and in vivo diversity, we estimate that inherent heterogeneity in viral production by the first infected cells may contribute to 23%–44% of the dissemination bottleneck. However, the majority of the heterogeneity in viral spread in vivo (56%–77%) likely arises from heterogeneity in spread in local microenvironments. IMPORTANCE: A brief window for viral clearance exists immediately following HIV transmission, where low levels of virus and infected cells are present. Understanding the bottlenecks encountered by the virus during this window is essential when designing therapies for this early period. We used a barcoded simian immunodeficiency virus infection model to track the early dissemination of multiple viral lineages in rhesus macaques. We observed up to a 10 5 -fold difference in the viral load of transmitted lineages within a single animal 2 weeks after infection, suggesting that early bottlenecks induced very different trajectories of initial growth. By comparing lineage size diversity under multiple experimental conditions, we conclude that around a quarter of the diversity in lineage size results from early cellular infection events, with the remainder likely attributable to differences between initial anatomical sites of infection in vivo .
- 24 March 2026
- Published by American Society for Microbiology in Journal of Virology
- Vol. 100 (3) , e0148525
Open AccessDissecting the steps in early simian immunodeficiency virus dissemination following mucosal and intravenous infection of rhesus macaques
Early HIV infection involves the transmission of a small number of virions and the subsequent expansion and spread of the virus. The early phases of infection represent an important opportunity for viral control, although relatively little is understood about the determinants of the rate of spread or the “bottlenecks” the virus must negotiate during this time. Here, we use the barcoded simian immunodeficiency virus (SIV) infection model to analyze the kinetics of early SIV infection in vitro and in vivo . We analyze the trajectories of multiple individual barcode lineages across in vitro infection of cell lines and primary cells and after mucosal and intravenous infection of macaques. We observe a large distribution in lineage sizes when an infection is founded by multiple different viral lineages, which we presume results from bottleneck-induced variability in early growth between lineages. Surprisingly, we find that lineage heterogeneity is similar after mucosal and intravenous infection, indicating that dissemination bottlenecks present in the genital tract are not grossly different from those encountered during seeding of systemic tissues. Comparing in vitro and in vivo diversity, we estimate that inherent heterogeneity in viral production by the first infected cells may contribute to 23%–44% of the dissemination bottleneck. However, the majority of the heterogeneity in viral spread in vivo (56%–77%) likely arises from heterogeneity in spread in local microenvironments. IMPORTANCE: A brief window for viral clearance exists immediately following HIV transmission, where low levels of virus and infected cells are present. Understanding the bottlenecks encountered by the virus during this window is essential when designing therapies for this early period. We used a barcoded simian immunodeficiency virus infection model to track the early dissemination of multiple viral lineages in rhesus macaques. We observed up to a 10 5 -fold difference in the viral load of transmitted lineages within a single animal 2 weeks after infection, suggesting that early bottlenecks induced very different trajectories of initial growth. By comparing lineage size diversity under multiple experimental conditions, we conclude that around a quarter of the diversity in lineage size results from early cellular infection events, with the remainder likely attributable to differences between initial anatomical sites of infection in vivo .
- Open Access
- 29 January 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound
HIV/SIV-specific CD8 + T cell responses are typically unable to control viral rebound following antiretroviral therapy (ART) interruption (ATI). To investigate whether enhancing the magnitude and activation of SIV-specific CD8 + T cells at the time of ATI can improve the immune interception of reactivating SIV infections, we vaccinated SIVmac239-infected rhesus macaques (RMs) on ART, boosting immediately prior to ATI, with a nucleoside-unmodified mRNA vaccine expressing SIVmac239 Gag (mRNA/SIVgag) alone or in combination with Nef (mRNA/SIVnef) and Pol (mRNA/SIVpol). The mRNA/SIVgag vaccine was effective in boosting Gag-specific CD8 + T cells in blood and lymphoid tissues. Following ATI, the mRNA/SIVgag vaccine group showed a significant delay in time to measurable viral rebound compared with controls and manifested lower plasma viral loads (PVLs) for up to 6 weeks after rebound. Similarly, RMs that received mRNA/SIVgag, mRNA/SIVnef, and mRNA/SIVpol also manifested a delay in SIV rebound compared with controls, suggesting that boosting SIV-specific CD8 + T cells during ATI can enhance early immune targeting of reactivating SIV infections. However, viral control was not sustained long term as PVLs were similar across vaccinees and controls by 24 weeks after rebound, highlighting the need for adjunctive therapies to improve the durability of virologic control elicited by CD8 + T cell–targeting vaccines.
- 29 January 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
Open AccessBoosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound
HIV/SIV-specific CD8 + T cell responses are typically unable to control viral rebound following antiretroviral therapy (ART) interruption (ATI). To investigate whether enhancing the magnitude and activation of SIV-specific CD8 + T cells at the time of ATI can improve the immune interception of reactivating SIV infections, we vaccinated SIVmac239-infected rhesus macaques (RMs) on ART, boosting immediately prior to ATI, with a nucleoside-unmodified mRNA vaccine expressing SIVmac239 Gag (mRNA/SIVgag) alone or in combination with Nef (mRNA/SIVnef) and Pol (mRNA/SIVpol). The mRNA/SIVgag vaccine was effective in boosting Gag-specific CD8 + T cells in blood and lymphoid tissues. Following ATI, the mRNA/SIVgag vaccine group showed a significant delay in time to measurable viral rebound compared with controls and manifested lower plasma viral loads (PVLs) for up to 6 weeks after rebound. Similarly, RMs that received mRNA/SIVgag, mRNA/SIVnef, and mRNA/SIVpol also manifested a delay in SIV rebound compared with controls, suggesting that boosting SIV-specific CD8 + T cells during ATI can enhance early immune targeting of reactivating SIV infections. However, viral control was not sustained long term as PVLs were similar across vaccinees and controls by 24 weeks after rebound, highlighting the need for adjunctive therapies to improve the durability of virologic control elicited by CD8 + T cell–targeting vaccines.
- Open Access
Dissecting the steps in early Simian Immunodeficiency Virus dissemination following mucosal and intravenous infection of rhesus macaques
In cases of HIV transmission, the typical delay from exposure to detectable viremia is approximately one week. This delay from exposure to viremia suggests that during initial expansion of virus from a limited number of founder lineages, there exists a period of low infected cell population. It is during this period of low infected cell population that the virus may be more vulnerable to clearance via primed immune responses targeting infected cells (e.g., antibody-dependent cellular cytotoxicity (ADCC) or CD8 + T cell killing/suppression). Potential future prophylactic harnessing of these immune mechanisms for early virally infected cell clearance will rely on an understanding of the earliest stages of viral replication and dissemination. The factors that dictate the rate of early viral spread, termed the ‘dissemination bottleneck’ could include target-cell-mediated effects, the anatomical microenvironment, or the organ of the first infected cells. In this study, we use the barcoded Simian Immunodeficiency Virus (SIV) infection model to assess the contribution of various anatomical and cellular mechanisms to the SIV dissemination bottleneck. Viral, cellular, and anatomically-mediated heterogeneity in viral replication each introduce a degree of variability into the early phases of viral spread, and when multiple founder lineages are present, this variability in early growth results in a large distribution in lineage sizes. Therefore, we use a comparison of viral lineage size variability across multiple experimental SIV infection models to examine the relative contribution to the overall dissemination bottleneck of viral-mediated stochasticity of cellular infection (e.g., integration site), infected cell phenotype (e.g., activation state), anatomical variability, and initial viral spread within the genital tract. We estimate that inherent heterogeneity in viral production by infected cells corresponds to 23 to 44% of the dissemination bottleneck, but the majority (56 to 77%) arises from anatomical heterogeneity (presumably heterogeneity in how conducive local microenvironments are to viral replication). Author Summary: A brief window exists immediately following HIV transmission where low initial levels of virus and infected cells may be susceptible to immune clearance. A better understanding of the bottlenecks encountered by the virus during this window is necessary when designing therapies to clear HIV during this early period. We used a barcoded Simian Immunodeficiency Virus (SIV) infection model to track the early dissemination of multiple viral lineages after mucosal and intravenous inoculation. We observed up to 10 5 -fold differences in lineage size between transmitted barcodes within a single animal two weeks after infection, suggesting very different trajectories of virial growth. By comparing lineage size diversity after mucosal and intravenous transmission and in vitro replication, we determined the contribution of anatomical and cellular mechanisms to the relative growth of different clonotypes. Although we expected that the processes of local dissemination may lead to greater lineage size diversity after mucosal transmission, this was not the case, and we saw no difference compared to intravenous transmission. We found that around a quarter of the diversity in clonotype size could be attributed to early cellular infection events, with the remainder likely attributable to differences in clonotype specific establishment and dissemination in vivo.
Open AccessDissecting the steps in early Simian Immunodeficiency Virus dissemination following mucosal and intravenous infection of rhesus macaques
In cases of HIV transmission, the typical delay from exposure to detectable viremia is approximately one week. This delay from exposure to viremia suggests that during initial expansion of virus from a limited number of founder lineages, there exists a period of low infected cell population. It is during this period of low infected cell population that the virus may be more vulnerable to clearance via primed immune responses targeting infected cells (e.g., antibody-dependent cellular cytotoxicity (ADCC) or CD8 + T cell killing/suppression). Potential future prophylactic harnessing of these immune mechanisms for early virally infected cell clearance will rely on an understanding of the earliest stages of viral replication and dissemination. The factors that dictate the rate of early viral spread, termed the ‘dissemination bottleneck’ could include target-cell-mediated effects, the anatomical microenvironment, or the organ of the first infected cells. In this study, we use the barcoded Simian Immunodeficiency Virus (SIV) infection model to assess the contribution of various anatomical and cellular mechanisms to the SIV dissemination bottleneck. Viral, cellular, and anatomically-mediated heterogeneity in viral replication each introduce a degree of variability into the early phases of viral spread, and when multiple founder lineages are present, this variability in early growth results in a large distribution in lineage sizes. Therefore, we use a comparison of viral lineage size variability across multiple experimental SIV infection models to examine the relative contribution to the overall dissemination bottleneck of viral-mediated stochasticity of cellular infection (e.g., integration site), infected cell phenotype (e.g., activation state), anatomical variability, and initial viral spread within the genital tract. We estimate that inherent heterogeneity in viral production by infected cells corresponds to 23 to 44% of the dissemination bottleneck, but the majority (56 to 77%) arises from anatomical heterogeneity (presumably heterogeneity in how conducive local microenvironments are to viral replication). Author Summary: A brief window exists immediately following HIV transmission where low initial levels of virus and infected cells may be susceptible to immune clearance. A better understanding of the bottlenecks encountered by the virus during this window is necessary when designing therapies to clear HIV during this early period. We used a barcoded Simian Immunodeficiency Virus (SIV) infection model to track the early dissemination of multiple viral lineages after mucosal and intravenous inoculation. We observed up to 10 5 -fold differences in lineage size between transmitted barcodes within a single animal two weeks after infection, suggesting very different trajectories of virial growth. By comparing lineage size diversity after mucosal and intravenous transmission and in vitro replication, we determined the contribution of anatomical and cellular mechanisms to the relative growth of different clonotypes. Although we expected that the processes of local dissemination may lead to greater lineage size diversity after mucosal transmission, this was not the case, and we saw no difference compared to intravenous transmission. We found that around a quarter of the diversity in clonotype size could be attributed to early cellular infection events, with the remainder likely attributable to differences in clonotype specific establishment and dissemination in vivo.
- Open Access
- 22 August 2024
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 20 (8) , e1012496
Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence
Persistence of the rebound-competent viral reservoir (RCVR) within the CD4+ T cell compartment of people living with HIV remains a major barrier to HIV cure. Here, we determined the effects of the pan-lymphocyte-depleting monoclonal antibody (mAb) alemtuzumab on the RCVR in SIVmac239-infected rhesus macaques (RM) receiving antiretroviral therapy (ART). Alemtuzumab administered during chronic ART or at the time of ART initiation induced >95% depletion of circulating CD4+ T cells in peripheral blood and substantial CD4+ T cell depletion in lymph nodes. However, treatment was followed by proliferation and reconstitution of CD4+ T cells in blood, and despite ongoing ART, levels of cell-associated SIV DNA in blood and lymphoid tissues were not substantially different between alemtuzumab-treated and control RM after immune cell reconstitution, irrespective of the time of alemtuzumab treatment. Upon ART cessation, 19 of 22 alemtuzumab-treated RM and 13 of 13 controls rebounded with no difference in the time to rebound between treatment groups. Time to rebound and reactivation rate was associated with plasma viral loads (pVLs) at time of ART initiation, suggesting lymphocyte depletion had no durable impact on the RCVR. However, 3 alemtuzumab-treated RM that had lowest levels of pre-ART viremia, failed to rebound after ART withdrawal, in contrast to controls with similar levels of SIV replication. These observations suggest that alemtuzumab therapy has little to no ability to reduce well-established RCVRs but may facilitate RCVR destabilization when pre-ART virus levels are particularly low.
- 22 August 2024
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 20 (8) , e1012496
Open AccessImpact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence
Persistence of the rebound-competent viral reservoir (RCVR) within the CD4+ T cell compartment of people living with HIV remains a major barrier to HIV cure. Here, we determined the effects of the pan-lymphocyte-depleting monoclonal antibody (mAb) alemtuzumab on the RCVR in SIVmac239-infected rhesus macaques (RM) receiving antiretroviral therapy (ART). Alemtuzumab administered during chronic ART or at the time of ART initiation induced >95% depletion of circulating CD4+ T cells in peripheral blood and substantial CD4+ T cell depletion in lymph nodes. However, treatment was followed by proliferation and reconstitution of CD4+ T cells in blood, and despite ongoing ART, levels of cell-associated SIV DNA in blood and lymphoid tissues were not substantially different between alemtuzumab-treated and control RM after immune cell reconstitution, irrespective of the time of alemtuzumab treatment. Upon ART cessation, 19 of 22 alemtuzumab-treated RM and 13 of 13 controls rebounded with no difference in the time to rebound between treatment groups. Time to rebound and reactivation rate was associated with plasma viral loads (pVLs) at time of ART initiation, suggesting lymphocyte depletion had no durable impact on the RCVR. However, 3 alemtuzumab-treated RM that had lowest levels of pre-ART viremia, failed to rebound after ART withdrawal, in contrast to controls with similar levels of SIV replication. These observations suggest that alemtuzumab therapy has little to no ability to reduce well-established RCVRs but may facilitate RCVR destabilization when pre-ART virus levels are particularly low.
- Open Access
- 1 April 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (7)
Anti–PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers
Programmed cell death protein 1 (PD-1) is an immune checkpoint marker commonly expressed on memory T cells and enriched in latently HIV-infected CD4 + T cells. We engineered an anti–PD-1 chimeric antigen receptor (CAR) to assess the impact of PD-1 depletion on viral reservoirs and rebound dynamics in SIVmac239–infected rhesus macaques (RMs). Adoptive transfer of anti–PD-1 CAR T cells was done in 2 SIV-naive and 4 SIV-infected RMs on antiretroviral therapy (ART). In 3 of 6 RMs, anti–PD-1 CAR T cells expanded and persisted for up to 100 days concomitant with the depletion of PD-1 + memory T cells in blood and tissues, including lymph node CD4 + follicular helper T (TFH) cells. Loss of TFH cells was associated with depletion of detectable SIV RNA from the germinal center (GC). However, following CAR T infusion and ART interruption, there was a marked increase in SIV replication in extrafollicular portions of lymph nodes, a 2-log higher plasma viremia relative to controls, and accelerated disease progression associated with the depletion of CD8 + memory T cells. These data indicate anti–PD-1 CAR T cells depleted PD-1 + T cells, including GC TFH cells, and eradicated SIV from this immunological sanctuary.
- 1 April 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (7)
Open AccessAnti–PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers
Programmed cell death protein 1 (PD-1) is an immune checkpoint marker commonly expressed on memory T cells and enriched in latently HIV-infected CD4 + T cells. We engineered an anti–PD-1 chimeric antigen receptor (CAR) to assess the impact of PD-1 depletion on viral reservoirs and rebound dynamics in SIVmac239–infected rhesus macaques (RMs). Adoptive transfer of anti–PD-1 CAR T cells was done in 2 SIV-naive and 4 SIV-infected RMs on antiretroviral therapy (ART). In 3 of 6 RMs, anti–PD-1 CAR T cells expanded and persisted for up to 100 days concomitant with the depletion of PD-1 + memory T cells in blood and tissues, including lymph node CD4 + follicular helper T (TFH) cells. Loss of TFH cells was associated with depletion of detectable SIV RNA from the germinal center (GC). However, following CAR T infusion and ART interruption, there was a marked increase in SIV replication in extrafollicular portions of lymph nodes, a 2-log higher plasma viremia relative to controls, and accelerated disease progression associated with the depletion of CD8 + memory T cells. These data indicate anti–PD-1 CAR T cells depleted PD-1 + T cells, including GC TFH cells, and eradicated SIV from this immunological sanctuary.
- Open Access
- 6 October 2023
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 19 (10) , e1011660
Timing of initiation of anti-retroviral therapy predicts post-treatment control of SIV replication
One approach to ‘functional cure’ of HIV infection is to induce durable control of HIV replication after the interruption of antiretroviral therapy (ART). However, the major factors that determine the viral ‘setpoint’ level after treatment interruption are not well understood. Here we combine data on ART interruption following SIV infection for 124 total animals from 10 independent studies across 3 institutional cohorts to understand the dynamics and predictors of post-treatment viral control. We find that the timing of treatment initiation is an important determinant of both the peak and early setpoint viral levels after treatment interruption. During the first 3 weeks of infection, every day of delay in treatment initiation is associated with a 0.22 log10 copies/ml decrease in post-rebound peak and setpoint viral levels. However, delay in initiation of ART beyond 3 weeks of infection is associated with higher post-rebound setpoint viral levels. For animals treated beyond 3 weeks post-infection, viral load at ART initiation was the primary predictor of post-rebound setpoint viral levels. Potential alternative predictors of post-rebound setpoint viral loads including cell-associated DNA or RNA, time from treatment interruption to rebound, and pre-interruption CD8+ T cell responses were also examined in the studies where these data were available. This analysis suggests that optimal timing of treatment initiation may be an important determinant of post-treatment control of HIV.
- 6 October 2023
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 19 (10) , e1011660
Open AccessTiming of initiation of anti-retroviral therapy predicts post-treatment control of SIV replication
One approach to ‘functional cure’ of HIV infection is to induce durable control of HIV replication after the interruption of antiretroviral therapy (ART). However, the major factors that determine the viral ‘setpoint’ level after treatment interruption are not well understood. Here we combine data on ART interruption following SIV infection for 124 total animals from 10 independent studies across 3 institutional cohorts to understand the dynamics and predictors of post-treatment viral control. We find that the timing of treatment initiation is an important determinant of both the peak and early setpoint viral levels after treatment interruption. During the first 3 weeks of infection, every day of delay in treatment initiation is associated with a 0.22 log10 copies/ml decrease in post-rebound peak and setpoint viral levels. However, delay in initiation of ART beyond 3 weeks of infection is associated with higher post-rebound setpoint viral levels. For animals treated beyond 3 weeks post-infection, viral load at ART initiation was the primary predictor of post-rebound setpoint viral levels. Potential alternative predictors of post-rebound setpoint viral loads including cell-associated DNA or RNA, time from treatment interruption to rebound, and pre-interruption CD8+ T cell responses were also examined in the studies where these data were available. This analysis suggests that optimal timing of treatment initiation may be an important determinant of post-treatment control of HIV.